Page 181 - 80_01

Dry
eye
disease
compounds…

72. Dor JP, Nivaggioli T, Reilly P, et al. mTOR pathway inhibitors for treating
ocular disorders. WO2010129622 (2010)
73. Cao GF, Liu Y, Yang W, et al. Rapamycin sensitive mTOR activation mediates
nerve growth factor (NGF) induced cell migration and pro-survival effects against
hydrogen peroxide in retinal pigment epithelial cells. Biochem Biophys Res Commun.
414(3), 499-505 (2011).
74. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of
intravitreal and subconjunctival injections of sirolimus in patients with non-infectious
uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 3(1),
32 (2013).
75. Bowman ML, Hosseini K, Pham S, et al. Non-steroidal anti-inflammatory
ophthalmic compositions. WO2010102192 (2010)
76. Urech DM. Functionalized polypeptides. WO2010006454 (2010)
77. Ottiger M, Thiel MA, Feige U, et al. Efficient intraocular penetration of topical
anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment
without penetration enhancer. Invest Ophthalmol Vis Sci. 50(2), 779-86 (2009).
78. Thiel MA, Wild A, Schmid MK, et al. Penetration of a topically administered
anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the
human eye. Ophthalmology. 120(7), 1403-8 (2013).
79. Choi SM, Seo MJ, Lee YG, et al. Effects of DA-6034, a flavonoid derivative, on
mucin-like glycoprotein and ocular surface integrity in a rabbit model.
Arzneimittelforschung. 59(10), 498-503 (2009).
80. Seo MJ, Kim JM, Lee MJ, et al. The therapeutic effect of DA-6034 on ocular
inflammation via suppression of MMP-9 and inflammatory cytokines and activation of
the MAPK signaling pathway in an experimental dry eye model. Curr Eye Res. 35(2),
165-75 (2010).
81. Lan W, Petznick A, Heryati S, et al. Nuclear Factor-kappaB: central regulator in
ocular surface inflammation and diseases. Ocul Surf. 10(3), 137-48 (2012).
82. Gjorstrup P. Compositions and methods for the treatment of ophthalmic
conditions. US2009011824 (2009)
83. Therapeutics C. Developing therapies for critical unmet medical needs. RX
10045 - Dry Eye and Allergic Conjunctivitis.
http://www.celtictherapeutics.com/RX100452012.
84. Pharmaceuticals R. RX-10045 http://www.resolvyx.com/products/rx-
10045.asp2013.
85. Hong W, Yan S. Engineering Streptomyces tenebrarius to synthesize single
component of carbamoyl tobramycin. Lett Appl Microbiol. 55(1), 33-9 (2012).
86. Wang H, Pang B, Li Y, et al. Dexamethasone has variable effects on
mesenchymal stromal cells. Cytotherapy. 14(4), 423-30 (2012).
87. Kabra B. Topical ophthalmic compositions containing tobramycin and
dexamethasone. US20107795316 (2010)
88. Wong B. JAK kinase inhibitors and their uses. US20060270694 (2006)
89. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates
psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 183(3), 2183-92
(2009).

177